Cancers · 2026
Tumor Mutational Burden as a Prognostic Biomarker in Follicular Lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lafuente Marta, Diez-Feijóo Ramón, García-Recio Marta, Garcia-Gisbert Nieves, Fernández-Rodríguez Maria Concepción, Longarón Raquel, Ji Junjie, Tazon-Vega Bárbara, Pinzón Sergio, Fernández-Ibarrondo Lierni, Sánchez-González Blanca, Camacho Laura, Gibert Joan, Gutierrez Antonio, Bellosillo Beatriz, Salar Antonio
Аннотация
INTRODUCTION: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Approximately 20% of patients experience early relapse within 24 months (POD24) of immunochemotherapy (ICT), a subgroup associated with poor prognosis and not well-identified by current prognostic indices. Given that tumor mutational burden (TMB) has been associated with outcome in various cancers, we investigated its potential as a prognostic biomarker in FL.
METHODS: TMB was estimated by next-generation sequencing using a 409-gene panel in a cohort of 119 patients diagnosed with FL grades 1-3A and treated with frontline immunotherapy or ICT.
RESULTS: Although TMB was not associated with clinical variables in non-transformed FL patients, higher TMB values were observed in patients harboring the t(14;18) translocation, mutations in BCL2, TNFRSF14, or genes involved in cellular migration (GNA13, GNAI2). Notably, patients with high TMB (>2.55 mutations per megabase) showed longer progression-free survival, lymphoma-specific survival, and overall survival, and had fewer mutations affecting the mTORC1 pathway. A higher proportion of POD24 patients was observed in the low TMB subgroup. In 25 paired diagnosis-relapse samples, TMB remained globally stable, although variations in the molecular landscape were observed. In addition, we analyzed TMB in a separate cohort of patients presenting transformed FL at diagnosis (n = 16). Higher TMB was also associated with the t(14;18) chromosomal translocation, but not with clinical features or survival.
CONCLUSIONS: These findings support the potential of TMB as a prognostic biomarker in FL, providing molecular understanding beyond established clinical indices and aiding in the identification of patients at higher risk of early progression following ICT.
METHODS: TMB was estimated by next-generation sequencing using a 409-gene panel in a cohort of 119 patients diagnosed with FL grades 1-3A and treated with frontline immunotherapy or ICT.
RESULTS: Although TMB was not associated with clinical variables in non-transformed FL patients, higher TMB values were observed in patients harboring the t(14;18) translocation, mutations in BCL2, TNFRSF14, or genes involved in cellular migration (GNA13, GNAI2). Notably, patients with high TMB (>2.55 mutations per megabase) showed longer progression-free survival, lymphoma-specific survival, and overall survival, and had fewer mutations affecting the mTORC1 pathway. A higher proportion of POD24 patients was observed in the low TMB subgroup. In 25 paired diagnosis-relapse samples, TMB remained globally stable, although variations in the molecular landscape were observed. In addition, we analyzed TMB in a separate cohort of patients presenting transformed FL at diagnosis (n = 16). Higher TMB was also associated with the t(14;18) chromosomal translocation, but not with clinical features or survival.
CONCLUSIONS: These findings support the potential of TMB as a prognostic biomarker in FL, providing molecular understanding beyond established clinical indices and aiding in the identification of patients at higher risk of early progression following ICT.